Experimental Autoimmune Uveitis

Uveitis is an inflammatory disease of the uvea that can affect individuals of all ages, genders, and genetic backgrounds. Non-infectious uveitis is often associated with systemic autoimmune disorders, where immune responses are triggered by ocular antigens. It represents a major public health concern as one of the leading causes of vision loss. Current treatment options include corticosteroids and immunosuppressive drugs, but these therapies carry significant systemic side effects and often provide insufficient efficacy.

Model Overview

At EyeCRO, experimental autoimmune uveitis (EAU) is induced in B10.RIII mice by immunization with the human IRBP peptide. The presence of this peptide elicits a transient CD4+ T-cell mediated ocular autoimmune response, with peak disease occurring from approximately 11 to 18 days post-immunization. This model recapitulates key features of human posterior uveitis, including retinal inflammation, immune cell infiltration, and photoreceptor damage, making it a valuable platform for evaluating immunomodulatory and anti-inflammatory therapeutics.

Typical Endpoints

  • Clinical fundus scoring of disease severity
  • Histopathological grading of retinal inflammation
  • OCT imaging (retinal structure and thickness)
  • Fluorescein angiography (vascular leakage)
  • Inflammatory cytokine analysis

Representative Data

Interested in this model?
We are happy to share more about study design options, endpoints, or timelines.
Contact us to discuss your study goals.